Resources

But lifestyle modification still needs to be the cornerstone of therapy.

Benefits of islet transplantation appear to be long lasting, greater than 2 years sofar.

Metformin monotherapy results in fewer fatal and non-fatal cardiovascular (CV) events compared to sulfonylurea monotherapy in new users of these agents.

Light drinking appears to have preventive effects on atherosclerosis among type 2 diabetic patients. These effects do not exist with heavy drinking, however.

Treatment of post-challenge glucose (PCG) levels may reduce cardiovascular disease and mortality associated with type 2 diabetes.

Results of the Heart Protection Study provide strong evidence for aggressively managing cardiovascular risk in type 2 diabetic patients.

Can treating AGEs lead to a reduction of endothelial dysfunction?

This information could save about 50,000 lives a year — that is, a thousand each week.”

New research shows that cardiovascular risks can increase even before patients develop diabetes.

Increasing daily aspirin use to 90% of those with Type 2 diabetes could prevent an additional 11,000 MIs and potentially save >8,000 lives.